AINewsStartup

Japanese Health Tech Startup Craif Raises ¥5.3 Billion Series D for AI-Powered Cancer Detection

Craif, a Japanese health technology company specializing in AI-powered cancer risk detection from urine samples, has raised approximately ¥5.3 billion (around $36 million) in a Series D global round. The funding, announced on August 18, 2026, will support the company’s U.S. product launch and domestic business expansion, bringing Craif’s cumulative fundraising total to approximately ¥14.2 billion since inception.

Key Takeaways

  • Craif raised ¥5.3 billion in Series D funding for its AI-powered urine microRNA cancer detection platform “miSignal.”
  • The round was co-led by Singapore’s Granite Integral Capital and Towns, with participation from multiple Japanese regional banks and existing investors.
  • Funds will support U.S. expansion, clinical development for pancreatic cancer SaMD approval, and domestic R&D growth.

Global Round Structure

The Series D round comprises approximately ¥4.8 billion in third-party allotment and secondary transactions (including about ¥900 million in secondary sales) and ¥500 million in financing. New investors include Granite Integral Capital Pte. Ltd., Kodomo no Mori, Hokuyo Business Succession Fund (operated by Hokuyo Start-up No. 1 Fund), and individual investors. Existing investors Towns, X&KSK, Unreasonable Group, and Nagase Future Investments also participated. Loans were provided by Joyo Bank, Higashi-Nippon Bank, Hokuyo Bank, Hokkokubank, Nagoya Bank, and Japan Finance Corporation.

miSignal Platform: AI Analyzing MicroRNA

Craif’s flagship product, “miSignal Scan,” analyzes microRNA contained in urine using proprietary Bio-AI technology to evaluate cancer risks by organ type. The test can be completed at home with just a urine sample, regardless of location. The analysis platform comprehensively reads molecular signals contained in bodily fluids including urine. Distribution channels extend beyond individual consumers to medical institutions, drugstores, corporate welfare programs, and public funding through local governments. According to the company, miSignal is currently available at over 2,500 medical institutions and more than 4,700 drugstores and pharmacies nationwide.

U.S. Market Entry and Clinical Development Plans

The company will allocate the new funds to strengthen its R&D and clinical development capabilities in the United States, where it established its own Bio-AI lab in San Diego in April 2026. Craif is also pursuing regulatory approval for a pancreatic cancer Software as a Medical Device (SaMD) program, targeting insurance reimbursement and product launch in the U.S. market. In addition, the company aims to build a urine-based data analysis platform leveraging its proprietary urine data infrastructure.

Frequently Asked Questions

What is Craif’s miSignal Scan?

miSignal Scan is an AI-powered urine test that analyzes microRNA to detect multiple cancer risks by organ type. It can be done at home with a urine sample and is available at over 2,500 medical institutions across Japan.

How much has Craif raised in total?

Cumulative fundraising, including this Series D round, now stands at approximately ¥14.2 billion, comprising equity funding, loans, and grants.

What are Craif’s plans for the U.S. market?

Craif established a Bio-AI lab in San Diego in April 2026 and plans to use the Series D funds to pursue FDA approval for its pancreatic cancer detection technology as a medical device, targeting insurance reimbursement.

Source: The Bridge (BRIDGE)

Cover image generated by AI for illustrative purposes only.